Related Experiment Video
Updated: Jun 4, 2025
Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue
Published on: January 3, 2013
Comparison of Shared Class I HLA-Bound Noncanonical Neoepitopes between Normal and Neoplastic Tissues of Pancreatic
Tengyi Zhang1,2,3,4, Betul Celiker1,2,3,4, Yingkuan Shao1,2,5
1Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Purpose:
Developing T-cell or vaccine therapies for pancreatic ductal adenocarcinoma (PDAC) has been challenging because of a lack of knowledge regarding immunodominant, cancer-specific antigens as PDAC are characterized by a scarcity of genomic mutation-associated neoepitopes, and effective approaches to discover them are limited.
Experimental Design:
An advanced mass spectrometry approach was employed to compare the immunopeptidome of PDAC tissues and matched normal tissues from the same patients.
Results:
This study identified HLA class I-binding variant peptides derived from canonical proteins, which had single amino-acid substitutions not attributed to genetic mutations or RNA editing. These amino-acid substitutions appeared to result from translational errors. The variant peptides were predominantly found in tumor tissues, with certain peptides common among multiple patients. Importantly, several of these variant peptides were more immunogenic than their wild-type counterparts.
Conclusions:
The shared noncanonical neoepitopes identified in this study offer promising candidates for vaccine and T-cell therapy development, potentially providing new avenues for immunotherapy in PDAC. See related commentary by Yuan et al., p. 1821.
Insights
Researchers discovered novel cancer-specific antigens in pancreatic ductal adenocarcinoma (PDAC) by analyzing tumor tissues. These findings offer new targets for developing effective T-cell and vaccine immunotherapies for PDAC patients.
Area of Science:
- Oncology
- Immunology
- Proteomics
Background:
- Pancreatic ductal adenocarcinoma (PDAC) immunotherapy development is hindered by limited knowledge of cancer-specific antigens.
- PDAC tumors have few mutation-associated neoepitopes, and discovery methods are restricted.
Purpose of the Study:
- To identify novel cancer-specific antigens for PDAC immunotherapy.
- To explore immunogenic targets beyond traditional neoepitopes in PDAC.
Main Methods:
- Utilized advanced mass spectrometry to compare the immunopeptidome of PDAC and matched normal tissues.
- Analyzed HLA class I-binding peptides from canonical proteins with single amino acid substitutions.
Main Results:
- Identified variant peptides arising from translational errors, not genetic mutations or RNA editing.
- These variant peptides were more prevalent in tumor tissues and immunogenic than wild-type counterparts.
- Discovered shared noncanonical neoepitopes across multiple PDAC patients.
Conclusions:
- Shared noncanonical neoepitopes represent promising candidates for PDAC vaccine and T-cell therapies.
- This study provides new avenues for advancing immunotherapy strategies in pancreatic cancer.
- The identified variant peptides could enhance treatment efficacy for PDAC.
